echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Arthritis Rheumatol: Atherosclerosis Vascular Events in multi-center SLE queues

    Arthritis Rheumatol: Atherosclerosis Vascular Events in multi-center SLE queues

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    In previouspublished articles, about 10% of SLE patients develop atherosclerosis vascular events (AVE)The study was designed to investigate the annual incidence and potential risk factors of AVE in a multi-country, multi-ethnic SLE initial queueFrom 1999 to 2017, a large sLE patient queue consisting of 33 centres was followed up annuallyBased on evidence that SLE was inactive at a TIME in AVE and that imaging or pathologically typical atherosclerosis changes and/or other atherosclerosis elsewhere, AVEs were determined to be attributed to atherosclerosisThe analysis includes descriptive statistics, the incidence of AVE per 1000 patientyears, and a single- and multi-factor relative risk regression modelOf the 1,848 patients included in the group, 1,710 were followed at least once after entering the group, for a total of 13,666 patientsOf the 1710 patients, 3.6% had 1 or more AVEs attributed to atherosclerosis, with an incident rate of 4.6 per 1,000 patients per yearIn multi-factor analysis, the lower incidence of AVE was associated with antimalarial drugs (HR: 0.54 (95% CI 0.32, 0.91), while the higher incidence of AVE was associated with past vascular events (VE) (HR: 4.00,10.30) and the body mass index (BMI) and body mass index (BMI) (HR: 2.74 ,1.04,788)Past AVE increases the risk of subsequent AVE (HR 5.42 (3.17, 9.27), p 0.001)The prevalence and incidence of AVE in this study were much lower than previously published dataThis may be related to better control of disease activity and classic risk factors
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.